National Comprehensive Cancer Network
Pharmacy Program:
Educational Events & Programs
NCCN Clinical Practice Guidelines in Oncology Symposium: Non-Small Cell Lung Cancer
Highlights from a symposium hosted by the University of Michigan Comprehensive Cancer Center on September 12, 2008
Presenters
Workup, Prognostic Factors, and Markers
Gregory A. Otterson, MD
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute
at The Ohio State University
Columbus, Ohio
Therapy for Stages I, IIA, IIB, and IIIA (T3, N1) Non-Small Cell Lung Cancer
Andrew Chang, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer
David S. Ettinger, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Neoadjuvant Combined Modality Therapy for Potentially Resectable Stage III Non-Small Cell Lung Cancer
Mark G. Kris, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Management of Metastatic Non-Small Cell Lung Cancer
Jeffrey Crawford, MD
Duke Comprehensive Cancer Center
Durham, North Carolina
Faculty Disclosure Statements
Gregory A. Otterson, MD
Dr. Otterson has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the educational activity. He has received grant/research support from Abraxis Bioscience, Inc.; Genentech, Inc.; Onyx Pharmaceuticals, Inc.; Pharmacyclics; sanofi-aventis U.S.; and Schering-Plough Corporation. He has also served on the product/speakers’ bureau for Eli Lilly and Company and Genentech, Inc.
Dr. Otterson has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Andrew Chang, MD
Dr. Chang has disclosed that he has no financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the educational activity.
Dr. Chang has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
David S. Ettinger, MD
Dr. Ettinger has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity. He has served as a consultant and scientific advisor for AstraZeneca Pharmaceuticals Corporation; BioNumerik Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; ImClone Systems Incorporated; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation. He has also served as a scientific advisor for Pfizer Inc. and a consultant for sanofi-aventis U.S. He has served as a product/speakers’ bureau member for BioNumerik Pharmaceuticals, Inc.; Eli Lilly and Company; Genentech, Inc.; and Pfizer Inc., and has received grant/research support from Novartis Pharmaceuticals Corporation.
Dr. Ettinger has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Mark G. Kris, MD
Dr. Kris has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the educational activity. He has served as a consultant for Eli Lilly and Company and ImClone Systems Incorporated. He has also served as a scientific advisor Bristol-Myers Squibb Company and has presented a sponsored lecture for sanofi-aventis U.S.
Dr. Kris has indicated that his presentation will include discussion of investigational or unlabeled uses of a product.
Jeffrey Crawford, MD
Dr. Crawford has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the educational activity. He has served received grant/research support from and has served as a consultant and scientific advisor for Amgen Inc. He has also served as a consultant for Genentech, Inc.
Dr. Crawford has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Program Overview
Based on the deliberations of experts from 21 leading cancer centers, the NCCN Non-Small Cell Lung Cancer Guidelines provide sequential recommendations for the management of lung malignancies. This program will present these algorithms and focus on new approaches that have been incorporated into the guidelines, including the use of drugs, biologics, and diagnostics. The meeting format features the use of interactive audience participation via case scenarios to discuss the application of the guidelines and the data supporting specific recommendations.
Educational Objectives
Following this activity, participants should be able to:
- Describe the appropriate work-up for patients with non-small cell lung cancer
- Explain the surgical approaches to management based on site and stage at presentation and indications for surgery in non-small cell lung cancer
- State the role of pre- and postoperative radiation in combination with chemotherapy in the management of non-small cell lung cancer
- Summarize the role of adjuvant therapy for locally advanced disease
- Describe the current status of neoadjuvant chemotherapy for stage II/III non-small cell lung cancer
- Define the roles of new therapies in management strategies for metastatic non-small cell lung cancer
- Differentiate management of treatment of patients with local disease, locally advanced disease, and metastatic non-small cell lung cancer
Intended Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.
Activity Instructions
Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than December 22, 2009. There is no fee for participating in this activity.
Accreditation Information
Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
NCCN designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses
This activity is approved for 1.4 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.
Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
Release date: December 22, 2008
Expiration date: December 22, 2009
Commercial Support
Supported by educational grants from Abraxis BioScience, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech BioOncology and OSI Oncology, ImClone Systems, and sanofi-aventis US
E-mail
Print
Mark
|
|
|
|
|
|
|
||